dothelial electrical resistance (TER) across BMEC monolayer cultures, we found that VEGF increased sucrose permeability and decreased TER. VEGF also caused a loss of occludin and ZO-1 from the endothelial cell junctions and changed the staining pattern of the cell boundary. Western blot analysis of BMEC lysates revealed that the level of occludin but not of ZO-1 was lowered by VEGF treatment. These results suggest that VEGF increases BMEC monolayer permeability by reducing occludin expression and disrupting ZO-1 and occludin organization, which leads to tight junction disassembly. Occludin and ZO-1 appear to be downstream effectors of the VEGF signaling pathway. vascular permeability factor; blood-brain barrier; ZO-1; brain microvessel endothelial cell; vascular endothelial growth factor ENDOTHELIAL CELLS OF THE BRAIN vasculature form the blood-brain barrier that maintains the homeostasis of the central nervous system. These highly specialized endothelial cells form tight intercellular junctions and have minimal pinocytosis and no fenestra. Pathological conditions including brain tumors increase the permeability of the brain microvasculature and destroy the blood-brain barrier.
Vascular endothelial growth factor (VEGF) also increases the permeability of the microvasculature and stimulates endothelial cell growth (10, 17, 19, 22) . VEGF is a homodimeric 45-kDa glycoprotein (10, 17) that is secreted by a variety of cells including most tumor cells. It stimulates endothelial growth by interacting with plasma membrane receptors on vascular endothelial cells. Two VEGF receptors, fmslike tyrosine kinase (Flt-1) and the kinase insert domain-containing receptor (KDR), have been identified in humans, and a KDR homolog, fetal liver kinase (Flk-1), has been identified in mice (10, 17, 22) . Binding of VEGF to its receptors causes autotyrosine phosphorylation of the receptors and subsequent binding and phosphorylation of their downstream mediators. This leads to cell proliferation and permeability increases. In human umbilical vascular endothelial cell (HUVEC) monolayers, [ 14 C]albumin permeability is increased with VEGF treatment (13) . The permeability increase is associated with the disorganization of endothelial junction proteins and appears to involve the mitogen-activated protein kinase (MAPK) signal transduction pathway. The signal transduction pathway and molecular targets responsible for the VEGF permeability-increasing activity are not understood.
To understand the VEGF-mediated breakdown of the blood-brain barrier, we studied the effect of VEGF on cultured brain microvessel endothelial cells (BMECs). Cultured BMECs retain many of the features of the blood-brain barrier and have been used as in vitro models to study mechanisms that regulate the permeability of and drug transport across the bloodbrain barrier (2, 14) . In a previous study we found that VEGF increased the permeability of the BMEC monolayers to [ 14 C]sucrose, a paracellular pathway tracer (24) , which suggested that VEGF might affect tight junction assembly and increase permeability of the monolayer. In this study we examined the effect of VEGF on the expression and distribution of two tight junction proteins, ZO-1 [the first identified and best characterized tight junction-associated protein (1, 20) ] and occludin [a transmembrane tight junction protein in BMEC monolayer (17) ], and cytoskeletal actin filaments. We report that VEGF treatment significantly reduced the amount of ZO-1 and occludin located at tight junctions and altered the distribution of actin filaments in the BMEC monolayers. The levels of occludin but not ZO-1 were decreased by VEGF treatment.
METHODS

Materials.
MEM and Ham's F-12 medium were purchased from Mediatech (Washington, DC), collagenase-dispase and dispase from were Boehringer-Mannheim (Mannheim, Germany), [ 14 C]sucrose was from New England Nuclear-DuPont (Chicago, IL), recombinant human VEGF was from Prepro Tech (Rocky Hill, NJ), endothelial cell growth supplements were from Collaborative Biomedical Products (Becton-Dickinson Labware, Bedford, MA), rhodamine-phalloidin was from Molecular Probes (Eugene, OR), and rabbit antibodies to ZO-1, occludin, and actin were from Zymed (South San Francisco, CA). Monoclonal anti-tubulin antibodies were a gift from R. Himes (University of Kansas). All other reagents were purchased from Sigma (St. Louis, MO).
BMEC isolation and cell culture. BMECs were isolated from bovine brain gray matter by enzymatic digestion as described previously (2, 3) and were seeded at 50,000 cells per cm 2 onto 24-mm-diameter Transwell filter inserts (with 0.4-m pores) coated with collagen and fibronectin. Cells were cultured in 45% MEM, 45% F-12 medium, 10% plateletpoor horse serum, 50 g/ml gentamicin, 125 g/ml heparin, and 25 g/ml endothelial cell growth supplements. Cells were grown in a 37°C incubator with 5% CO 2 and 95% humidity. BMECs formed a monolayer by day 7 and a tight monolayer 8-9 days after plating. The formation of the monolayer and its tightness were judged by staining filamentous actin with rhodamine-phalloidin or by measuring [ 14 C]sucrose flux across the monolayer.
Paracellular permeability for sucrose and transendothelial electrical resistance measurement. Paracellular permeability for [
14 C]sucrose was determined as described previously (24) . The amount of radiolabeled tracer that penetrated the BMEC monolayers was expressed (%/cm 2 ) as follows
where C r is the count of the radiotracer appearing in the receiver chamber, C d is the count of the initial tracer in the donor chamber, V r is the volume (ml) of the medium in the receiver chamber, V d is the volume (ml) of the medium in the donor chamber, and A is the surface area of the filter support (4.71 cm 2 ). Transendothelial electrical resistance (TER) was measured using Endohm-snap (World Precision Instruments, New Haven, CT). Resistances of blank filters were subtracted from those of filters with cells before final TER values (cm 2 ) were calculated. All experiments were carried out in triplicate. The results were expressed as means Ϯ SD of n ϭ 3 experiments; P values were determined via ANOVA.
Immunocytochemistry. Immunofluorescent staining of occludin, ZO-1, and tubulin was performed using a modification of the protocol described by Stevenson and colleagues (20) . BMECs grown on Transwell filters were washed once with PBS containing 1 mM CaCl 2 (PBS-Ca). Cells were fixed by immersion in 95% ethanol (at Ϫ20°C) followed by incubation in ethanol at 4°C for 30 min. Cells were permeabilized in Ϫ20°C acetone for 1-2 min. Alternatively, cells were fixed for 20 min in 3.7% formaldehyde in PBS and then permeabilized in PBS with 0.1% Triton X-100 for 10 min at room temperature. Cells were blocked for 1 h with PBS-Ca containing 10% horse serum and 0.1% Tween 20. Permeabilized cells were incubated overnight at 4°C with primary antibodies. Rabbit anti-occludin antibodies were combined with PBS containing 0.2% horse serum and 0.1% Tween 20 in a 1:200 dilution, anti-ZO-1 at a 1:100 dilution, and mouse anti-tubulin at a 1:2,000 dilution. Cells were washed with PBS-Tween (PBS with 0.1% Tween 20) and stained with FITC-labeled secondary antibodies at a 1:100 dilution in PBS-Tween for 1 h at room temperature. Cells then were rinsed three times in PBS-Tween, mounted in 90% glycerol in PBS, and examined with a Zeiss WL epifluorescence microscope.
For actin staining, cells were fixed for 20 min in 3.7% formaldehyde in PBS and permeabilized in PBS with 0.1% Triton X-100 for 10 min at room temperature. Cells were washed three times with PBS and incubated for 60 min in rhodamine-phalloidin. Cells then were rinsed three times in PBS, mounted in 90% glycerol in PBS, and examined with a Zeiss WL epifluorescence microscope.
For ELISA analysis, BMEC monolayers were washed once with PBS-Ca, fixed for 30 min in 95% ethanol as described in the preceding text, and permeabilized with Ϫ20°C acetone for 1-2 min. Cells were blocked for 1 h with PBS-Ca containing 10% horse serum and 0.1% Tween 20, followed by overnight incubation with primary antibodies at 4°C. Anti-occludin antibodies were used at a 1:200 dilution, anti-ZO-1 was used at a 1:100 dilution, and rhodamine-phalloidin was used at a 1:100 dilution in PBS containing 0.2% horse serum and 0.1% Tween 20. Cells were washed with PBS-Tween and stained with horseradish peroxidase (HRP)-conjugated secondary antibodies at a 1:1,000 dilution for 1 h at 37°C. The cells were washed, and the color was developed in HRP substrate and quantified using a plate reader.
Protein and immunoblot analysis. Filter-grown BMECs were quickly rinsed with PBS-Ca, mixed with 400 l (per filter) of SDS-PAGE sample buffer, and heated to 100°C. To determine the protein concentration for SDS-PAGE loading, a filter of BMECs was lysed with 1% Triton X-100 and assayed using a Bio-Rad protein assay kit with BSA as a standard.
Equal amounts of protein were separated on 8% SDS-PAGE gels and transferred to nitrocellulose paper. The blots were incubated with antibodies against occludin (1:1,000 dilution), ZO-1 (1:1,000 dilution), actin (1:200 dilution), and tubulin (1:2,000 dilution) followed by incubation with alkaline phosphatase-conjugated secondary antibodies. Blots were developed with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP).
RESULTS
Development of tight junctions during BMEC culture.
To study the development and maintenance of tight junctions, BMECs were stained with antibodies against the tight junction proteins occludin and ZO-1. Because actin filaments play an important role in the organization of tight junctions, actin filaments were stained with rhodamine-phalloidin (Fig. 1) . Five days after seeding was completed, the BMECs were subconfluent. Actin filaments generally were organized as cytoplasmic stress fibers, although some peripheral actin filament staining was observed (Fig. 1A) . Occludin accumulated in the perinuclear cytoplasm, although it also was found at the periphery of some cells (Fig. 1D ). Most ZO-1 was distributed in discontinuous lines along the cell periphery near the sites of cell-tocell junction formation (Fig. 1G) .
After 7 days in culture, the BMECs reached confluence and acquired the elongated shape typical of primary cultured BMECs (2) . Cytoplasmic actin filaments disappeared, and actin filaments were predominantly found at the cell periphery (Fig. 1B) . Perinuclear occludin disappeared, and most occludin and ZO-1 lined the cell boundaries (Fig. 1, E and H) . After 9 days of culture (2 days after reaching confluence) all cells exhibited peripheral actin filament staining (Fig. 1C) . Occludin ( Fig. 1F ) and ZO-1 (Fig. 1I ) lined the cell boundaries and appeared as continuous lines. Therefore, ZO-1 preceded the appearance of occludin at junction sites during tight junction formation. Occludin moved from the perinuclear region to the lateral junction sites of the plasma membrane as tight junctions formed.
Alteration of the permeability and TER of BMEC monolayers by VEGF. VEGF was added to the basolateral sides of BMEC confluent monolayers, cells were cultured for an additional 2 days, and cells were then processed for sucrose permeability and TER analysis. VEGF treatment caused a twofold increase in [ 14 C]sucrose flux ( Fig. 2A) and a greater than threefold reduction in TER (Fig. 2B) . Identical molar concentrations of basic fibroblast growth factor (bFGF), which is also an endothelial growth factor but not a permeability modulator, did not significantly alter [ 14 C]sucrose permeability or the TER (Fig. 2, A and B) . Treatment of control and VEGF-treated monolayers with 1 mM EGTA for 10 min disrupted the electrical barrier and reduced the electrical resistance to values near that of naked Transwell filters (Fig. 2B) . When VEGF was added to the apical sides of the monolayers, there was no significant alteration of [ 14 C]sucrose permeability. Effect of VEGF on tight junction proteins occludin and ZO-1 in BMEC monolayers. To determine the structural basis for the permeability-increasing activity of VEGF, the distribution of actin filaments and microtubules was compared with that of ZO-1 and occludin. VEGF was added to the basolateral side of confluent BMEC monolayers, and cells were cultured for an additional 2 days and then fixed and processed for immunolabeling. Two-day treatments of VEGF were chosen because preliminary results revealed that it took at least 10 h of VEGF treatment to induce a change in sucrose flux. Sucrose flux peaked 1-2 days after the start of treatment.
VEGF shifted the distribution of actin filaments from the cell cortex in untreated cells (Fig. 3A) to a less-organized pattern of cytoplasmic filaments in treated cells (Fig. 3B) . Microtubule distribution was not altered by VEGF (compare Fig. 3, D and E) .
VEGF induced the redistribution of ZO-1 and occludin from the cell periphery to the cytoplasm. ZO-1, normally found along the cell boundaries (Fig. 3G) , became clustered in patchy aggregates in the cytoplasm after VEGF treatment (Fig. 3H) . Similarly, occludin, which was normally distributed along the periphery of cells (Fig. 3J) , was either absent or was found in faintly stained cytoplasmic aggregates (Fig.  3K) . Continuous lines of occludin and ZO-1 staining found along the cell-to-cell boundaries in control cells were rarely found after VEGF treatment. Cells treated with equimolar concentrations of bFGF looked identical to control cells and did not display altered patterns of actin, ZO-1, or occludin staining (Fig. 3, C, F, I , and L). When VEGF was added to the apical sides of confluent BMEC monolayers, there were no significant changes in the distribution of either occludin or ZO-1 (not shown). This is consistent with earlier observations that VEGF receptors are located on the basolateral sides of BMECs and that VEGF does not readily cross the cell monolayer (22) . These results indicate that VEGF specifically disrupted tight junction complexes in confluent BMEC monolayers.
Effect of VEGF on expression of cytoskeletal and tight junction proteins. VEGF-treated cells were further examined for the expression of tight junction proteins. VEGF was applied to the basolateral side of confluent BMEC monolayers, and cells were cultured for an additional 2 days. Control cells were cultured identically but were not treated with VEGF. Cells were then lysed, and equal amounts of control and VEGF-treated cells were analyzed on Western blots using antibodies to actin, tubulin, occludin, and ZO-1 (Fig. 4 ). There were no significant differences in actin and tubulin levels in control and VEGF-treated cells (Fig. 4, A and B) .
Occludin antibodies recognized several 55-to 70-kDa polypeptides in the control cells (Fig. 4C, left) , which is consistent with earlier observations that occludin appears as multiple bands between 62 and 82 kDa on Western blots (15, 16) . The occludin antibodies also identified three additional polypeptides of 50, 85, and 105 kDa. The 50-kDa polypeptide may be an occludin break-down product. ZO-1 antibodies recognized the two isoforms of ZO-1 that arise from alternative RNA splicing or to tyrosine phosphorylation concomitant with tight junction protein reorganization in A-431 cells (4, 23, 25) . Densitometric analysis of Western blots revealed that VEGF caused a 0.2% increase in actin (not significant), an 0.8% decrease in tubulin, a 32% decrease in occludin, and a 16% increase in ZO-1 staining. Therefore, VEGF induced no significant changes in actin and tubulin levels but VEGF significantly decreased occludin levels and led to a slight increase in ZO-1.
The levels of ZO-1, occludin, and actin were further examined via ELISA (Fig. 5) . These assays confirmed that VEGF had no significant effect on ZO-1 levels, but that it did significantly lower the levels of occludin and actin.
Taken together, these data suggest that VEGF induces permeability in BMEC monolayers by altering the organization of ZO-1 and occludin and by the subsequent loss of tight junctions between BMECs. 
DISCUSSION
Previously, we reported that VEGF increased the permeability of cultured BMECs to [ 14 C]sucrose and suggested that VEGF may alter tight junction assembly in the BMEC monolayers (24) . Here we report that VEGF treatment of BMEC monolayers disrupted the continuous pericellular distribution of the tight junction proteins ZO-1 and occludin as well as actin filament distribution. VEGF treatment also decreased occludin levels in BMECs. The protein levels of ZO-1, actin, or tubulin were not affected. These data suggest that VEGF induces tight junction disassembly and breakdown of the endothelial permeability barrier by altering the organization of tight junction proteins.
The mechanism by which VEGF disrupts tight junctions and increases permeability is not well understood. Several studies suggest that VEGF binding to endothelial cell receptors induces receptor dimerization, which then stimulates receptor autophosphorylation and the phosphorylation of downstream signal transduction proteins (22) . VEGF-activated endothelial cell receptors are known to phosphorylate several cytoplasmic proteins, including ones that contain receptor phosphotyrosine-binding Src homology 2 (SH2) domains that may be involved in signal transduction (12) . These signals may affect the expression and/or modification of proteins necessary for the maintenance of tight junctions. VEGF also induces rapid and transient elevation in cytosolic calcium in several types of cultured endothelial cells (8) . Elevation of calcium levels may activate calcium-calmodulin-dependent protein kinases to alter protein phosphorylation and/or affect the actin cytoskeleton, which is important in organizing adhesion junctions and tight junctions.
Tight junctions are highly dynamic structures with permeability, assembly, and disassembly characteristics that can be altered by a variety of cellular and metabolic regulators. Studies using protein kinase activators and inhibitors have revealed that protein phosphorylation plays an important role in tight junction assembly, maintenance, and function in epithelial (5) (6) (7) (8) 21 ) and endothelial (14) cells. Only recently have the phosphorylation levels of the tight junction proteins ZO-1 and occludin been correlated with tight junction assembly (6, 16) . The role of protein phosphorylation in the structure of BMEC tight junctions is under investigation at this time. Preliminary results reveal several changes in protein phosphorylation after VEGF treatment but identification of specific occludin and ZO-1 bands have not been made (Wang and Borchardt, unpublished data).
Sakakibara and colleagues (16) reported that mammalian occludin migrates as a series of closely spaced bands between 62 and 82 kDa and that the apparent molecular weight increases with the degree of phosphorylation. They also reported that increased levels of occludin phosphorylation are correlated with increased TER and tight junction assembly. In our study, antioccludin antibodies stained multiple bands between 55 and 70 kDa in control BMECs (with high TER). VEGF treatment decreases the high molecular weight bands, consistent with occludin dephosphorylation, and decreases TER values, consistent with tight junction disassembly.
The 105-kDa band recognized by occludin antibodies was not found in other endothelial cells and may be a factor that helps BMECs form tighter junctions than those in other tissues. The 85-kDa band may be a Fig. 5 . ELISA analysis of ZO-1, occludin, and actin levels in BMEC monolayers. Confluent BEMC monolayers were cultured without (open bars) or with (shaded bars) VEGF added to the basolateral sides for 2 days. Cells were fixed and stained with antibodies against ZO-1, occludin, and actin, followed by horseradish peroxidase-labeled secondary antibodies. The color of horseradish peroxidase substrate was quantified using a plate reader. Results are expressed as means Ϯ SD; n ϭ 3 experiments; *P Ͻ 0.01 significantly different from control. break-down product of the 105-kDa polypeptide, because VEGF treatment reduced staining of the 105-kDa band and increased staining of the 85-kDa band.
A recent study conducted by Kevil and colleagues (13) using HUVECs and [
14 C]albumin demonstrated that VEGF treatment increased the permeability of HUVEC monolayers to [ 14 C]albumin and disorganized endothelial junctional proteins. The VEGF-mediated permeability increase could be blocked by the MAPK inhibitors AG-126 and PD-98059, but G-6976 and staurosporine, protein kinase C antagonists, and wortmannin, a phosphatidylinositol 3-kinase blocker, did not block the effect of VEGF on HUVECs. Their study suggested that the MAPK signal transduction pathway is involved in the VEGF-induced permeability change. At present, we do not understand the VEGF-mediated pathways in BMECs, but in the future we will carry out a more thorough study of the role of VEGF-stimulated protein kinases to elucidate the signal transduction pathway in BMECs.
We observed that occludin levels in BMECs decreased during VEGF treatment, which suggests that VEGF either downregulates occludin synthesis or increases its degradation. Further analysis of occludin mRNA levels will help clarify the mechanism by which VEGF decreases occludin levels. VEGF did not alter the levels of ZO-1, which suggests that ZO-1 organization is regulated by other mechanisms.
Immunoblot assays of whole cell lysates revealed that actin levels were similar in control and VEGFtreated cells but that actin levels were lower in VEGFtreated cells analyzed with an ELISA assay. This is most likely due to the fixation and extraction method employed for ELISA: whole cell lysates contained both soluble and filamentous actin, but the extraction of cells necessary for ELISA likely released soluble actin and preserved the filamentous actin. These data suggest that VEGF affects the assembly but not the total amount of cellular actin and are consistent with our immunofluorescence data showing rearrangement of actin in VEGF-treated cells.
In addition to its permeability-increasing activity, VEGF is a mitogen that stimulates endothelial cell growth. We observed 10-20% increases in protein level, cell number, and [
3 H]thymidine incorporation in VEGF-treated cells (Wang and Borchardt, unpublished data). Light and electron microscopic analysis of the cells revealed that some cell clusters grew on top of the BMEC monolayers. Even in regions of cell clusters and layers of two or more cells, the cell layer was intact and tight junctions blocked penetration of lanthanum through the layers (Wang and Dentler, unpublished data). Cell migration and proliferation may weaken the tight junctions and increase permeability. We tried to separate the mitogenic effect of VEGF from the permeability-increasing activity by using colchicine to inhibit cell division and cytochalasins B and D to inhibit cell migration, but each of these drugs induced cells to round up which disrupted the confluent monolayers. These results reveal the importance of the actin and microtubular cytoskeleton in the maintenance of cell shape and tight junctions.
The VEGF-induced permeability increase also could be caused by an increase in endocytotic activity or in the transcellular trafficking in BMECs. In a preliminary study we found that VEGF treatment increased the uptake of the endocytotic marker Lucifer yellow by BMECs (Wang and Borchardt, unpublished data), so VEGF does increase endocytic activity. The degree of the contribution of the paracellular and transcellular pathways to the permeability increase described here remains to be determined. Although the mechanism or signal transduction pathway for the permeability-increasing effect of VEGF is not well understood, it is certain that VEGF increases the permeability of the BMEC monolayers and modifies the localization of the tight junction proteins occludin and ZO-1. We expect that an understanding of the mechanisms of VEGFinduced permeability will enable the use of VEGF and related agents to facilitate drug delivery to the brain, as well as the development of therapeutic drugs to intervene in the signal transduction pathway of VEGF for the treatment of brain and related tumors.
